XML 42 R31.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Information |
Summary of results of operations by segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Three Months Ended September 30, 2025 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 2,814 | ​ | $ | 485 | ​ | $ | — | ​ | $ | 3,299
Intercompany revenue | ​ | — | ​ | ​ | 4,130 | ​ | ​ | (4,130) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 4,454 | ​ | ​ | (3,916) | ​ | ​ | 538
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Bosakitug | ​ | 3,062 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,062
ATI-2138 | ​ | 1,469 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,469
ATI-052 | ​ | 1,837 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,837
Discovery | ​ | 2,340 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,340
Total Research and development project expenses | ​ | 8,708 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 8,708
Personnel | ​ | 2,993 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,993
Other research and development expense(1) | ​ | 1,541 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,541
Total research and development | ​ | 13,242 | ​ | ​ | — | ​ | ​ | (214) | ​ | ​ | 13,028
General and administrative | ​ | — | ​ | ​ | 467 | ​ | ​ | — | ​ | ​ | 467
Licensing | ​ | 1,911 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,911
Revaluation of contingent consideration | ​ | 100 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 100
Segment operating loss | $ | (12,439) | ​ | $ | (306) | ​ | $ | — | ​ | $ | (12,745)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 4,404
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2,535
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (14,614)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Three Months Ended September 30, 2024 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 3,701 | ​ | $ | 645 | ​ | $ | — | ​ | $ | 4,346
Intercompany revenue | ​ | — | ​ | ​ | 3,035 | ​ | ​ | (3,035) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 3,485 | ​ | ​ | (2,831) | ​ | ​ | 654
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ATI-2138 | ​ | 745 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 745
Discovery | ​ | 1,263 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,263
Total Research and development project expenses | ​ | 2,008 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,008
Personnel | ​ | 1,970 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,970
Other research and development expense(1) | ​ | 2,182 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,182
Total research and development | ​ | 6,160 | ​ | ​ | — | ​ | ​ | (204) | ​ | ​ | 5,956
General and administrative | ​ | — | ​ | ​ | 905 | ​ | ​ | — | ​ | ​ | 905
Licensing | ​ | 1,754 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,754
Revaluation of contingent consideration | ​ | 800 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 800
Segment operating loss | $ | (5,013) | ​ | $ | (710) | ​ | $ | — | ​ | $ | (5,723)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 4,748
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2,885
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (7,586)
| (1) | Other segment items for the Therapeutics segment consist primarily of the following research and development expenses: former development assets, stock-based compensation, depreciation and amortization, and regulatory.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Nine Months Ended September 30, 2025 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 5,159 | ​ | $ | 1,372 | ​ | $ | — | ​ | $ | 6,531
Intercompany revenue | ​ | — | ​ | ​ | 11,085 | ​ | ​ | (11,085) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 11,983 | ​ | ​ | (10,424) | ​ | ​ | 1,559
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Bosakitug | ​ | 9,293 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 9,293
ATI-2138 | ​ | 4,395 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,395
ATI-052 | ​ | 3,874 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,874
Discovery | ​ | 5,306 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,306
Total Research and development project expenses | ​ | 22,868 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 22,868
Personnel | ​ | 8,904 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 8,904
Other research and development expense(1) | ​ | 4,950 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,950
Total research and development | ​ | 36,722 | ​ | ​ | — | ​ | ​ | (661) | ​ | ​ | 36,061
General and administrative | ​ | — | ​ | ​ | 1,989 | ​ | ​ | — | ​ | ​ | 1,989
Licensing | ​ | 4,256 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,256
Revaluation of contingent consideration | ​ | 1,900 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,900
Segment operating loss | $ | (37,719) | ​ | $ | (1,515) | ​ | $ | — | ​ | $ | (39,234)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 14,407
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 8,513
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (45,128)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Nine Months Ended September 30, 2024 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 7,583 | ​ | $ | 1,926 | ​ | $ | — | ​ | $ | 9,509
Intercompany revenue | ​ | — | ​ | ​ | 10,122 | ​ | ​ | (10,122) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 11,558 | ​ | ​ | (9,471) | ​ | ​ | 2,087
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ATI-2138 | ​ | 1,560 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,560
Discovery | ​ | 4,408 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,408
Total Research and development project expenses | ​ | 5,968 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,968
Personnel | ​ | 9,002 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 9,002
Other research and development expense(1) | ​ | 10,241 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 10,241
Total research and development | ​ | 25,211 | ​ | ​ | — | ​ | ​ | (651) | ​ | ​ | 24,560
General and administrative | ​ | — | ​ | ​ | 3,033 | ​ | ​ | — | ​ | ​ | 3,033
Licensing | ​ | 4,070 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,070
Revaluation of contingent consideration | ​ | 3,800 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,800
Segment operating loss | $ | (25,498) | ​ | $ | (2,543) | ​ | $ | — | ​ | $ | (28,041)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 14,216
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 6,744
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (35,513)
| (1) | Other segment items for the Therapeutics segment consist primarily of the following research and development expenses: former development assets, stock-based compensation, depreciation and amortization, and regulatory.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration